日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Efficacy and safety of isatuximab subcutaneous plus carfilzomib and dexamethasone in patients with relapsed/refractory multiple myeloma: results of the Phase 2 study IZALCO

伊沙妥昔单抗皮下注射联合卡非佐米和地塞米松治疗复发/难治性多发性骨髓瘤患者的疗效和安全性:II期研究IZALCO的结果

Parmar, Gurdeep; Capra, Marcelo; Seguro, Fernanda; Hungria, Vania; Dimopoulos, Meletios-Athanasios; Delimpasi, Sosana; Minařík, Jiří; Špička, Ivan; Pour, Luděk; Marques, Herlander; Esteves, Graça; Sunami, Kazutaka; Yuda, Junichiro; Hájek, Roman; Mihályová, Jana; Soufflet, Christine; Yu, Disa; Benlhassan, Khadija; Koch, Victorine; Comerford, Erin; Cordero, Paul; Suzan, Florence; Quach, Hang

Modification of belantamab mafodotin dosing to balance efficacy and tolerability in the DREAMM-7 and DREAMM-8 trials

在 DREAMM-7 和 DREAMM-8 试验中调整 belantamab mafodotin 的剂量以平衡疗效和耐受性

Mateos, María-Victoria; Trudel, Suzanne; Quach, Hang; Robak, Paweł; Beksac, Meral; Pour, Ludek; Hus, Marek; Kim, Kihyun; Zherebtsova, Vera; Delimpasi, Sosana; Jelínek, Tomas; Ward, Christopher; Ho, P Joy; Vorobyev, Vladimir; Pitombeira de Lacerda, Marcelo; Aparecida-Martinez, Gracia; Spicka, Ivan; Radocha, Jakub; Cavo, Michele; Cerchione, Claudio; Fu, Chengcheng; Suzuki, Kazuhito; Rogers, Rachel; Phillips-Jones, Amy; Wang, Zhaohui; Baig, Hena; Wilkes, Jodie; Zhou, Xiaoou L; Lewis, Eric; Eccersley, Lydia; Sule, Neal; Paka, Prani; Opalinska, Joanna B; Mukhopadhyay, Pralay; Hungria, Vania; Dimopoulos, Meletios Athanasios

Lymphadenopathy is an independent prognostic factor for patients with Waldenström macroglobulinaemia

淋巴结肿大是华氏巨球蛋白血症患者的独立预后因素。

Ntanasis-Stathopoulos, Ioannis; Filippatos, Charalampos; Fotiou, Despina; Labropoulou, Vassiliki; Giannakoulas, Nikolaos; Spanoudakis, Emmanouil; Delimpasi, Sosanna; Migkou, Magdalini; Malandrakis, Panagiotis; Michael, Michalis; Giannouli, Stavroula; Hatjiharissi, Evdoxia; Katodritou, Eirini; Terpos, Evangelos; Kastritis, Efstathios; Dimopoulos, Meletios Athanasios; Gavriatopoulou, Maria

Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies?

OCEAN 和 HORIZON 试验中观察到的卓越长期疗效:在新型免疫疗法时代,melflufen-地塞米松能否为复发/难治性多发性骨髓瘤患者拓展治疗选择?

Talarico, M; Barbato, S; Maisnar, V; Delimpasi, S; Puppi, M; Rizzello, I; Pantani, L; Tacchetti, P; Martello, M; Vigliotta, I; Terragna, C; Cavo, M; Zamagni, Elena; Mancuso, K

Health-related quality of life in relapsed/refractory multiple myeloma treated with melflufen and dexamethasone: analyses from the phase III OCEAN study

接受美洛氟芬和地塞米松治疗的复发/难治性多发性骨髓瘤患者的健康相关生活质量:来自 III 期 OCEAN 研究的分析

Schjesvold, Fredrik H; Ludwig, Heinz; Delimpasi, Sossana; Robak, Pawel; Coriu, Daniel; Tomczak, Waldemar; Pour, Ludek; Spicka, Ivan; Dimopoulos, Meletios-Athanasios; Masszi, Tamas; Chernova, Natalia G; Sandberg, Anna; Thuresson, Marcus; Norin, Stefan; Bakker, Nicolaas A; Mateos, Maria-Victoria; Richardson, Paul G; Sonneveld, Pieter

Belantamab mafodotin: an important treatment option for vulnerable patients with triple class exposed relapsed and/or refractory multiple myeloma

Belantamab mafodotin:三线抗化疗暴露后复发和/或难治性多发性骨髓瘤脆弱患者的重要治疗选择

Mateos, Maria Victoria; Weisel, Katja; Terpos, Evangelos; Delimpasi, Sossana; Kastritis, Efstathios; Zamagni, Elena; Delforge, Michel; Ocio, Enrique; Katodritou, Eirini; Gay, Francesca; Larocca, Alessandra; Leleu, Xavier; Otero, Paula Rodriguez; Schjesvold, Fredik; Cavo, Michele; Dimopoulos, Meletios A

A.R.R.O.W.2: once- vs twice-weekly carfilzomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma

ARROW2:卡非佐米、来那度胺和地塞米松每周一次与每周两次治疗复发/难治性多发性骨髓瘤的比较

Dimopoulos, Meletios A; Coriu, Daniel; Delimpasi, Sosana; Špička, Ivan; Upchurch, Terry; Fang, Belle; Talpur, Rakhshandra; Faber, Edward; Beksac, Meral; Leleu, Xavier

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma based on prior lines of treatment and refractory status: IKEMA subgroup analysis

基于既往治疗方案和难治状态的复发性多发性骨髓瘤患者,伊沙妥昔单抗联合卡非佐米和地塞米松治疗的疗效:IKEMA亚组分析

Dimopoulos, Meletios A; Moreau, Philippe; Augustson, Bradley; Castro, Nelson; Pika, Tomas; Delimpasi, Sosana; De la Rubia, Javier; Maiolino, Angelo; Reiman, Tony; Martinez-Lopez, Joaquin; Martin, Thomas; Mikhael, Joseph; Yong, Kwee; Risse, Marie-Laure; Asset, Gaelle; Marion, Sylvia; Hajek, Roman

P38 PATIENT-REPORTED OUTCOMES (PRO) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) TREATED WITH MELFLUFEN AND DEXAMETHASONE (DEX) OR POMALIDOMIDE (POM) AND DEX: ANALYSES FROM THE PHASE 3 OCEAN STUDY

P38 复发/难治性多发性骨髓瘤 (RRMM) 患者报告结局 (PRO) 接受美洛氟芬和地塞米松 (DEX) 或泊马度胺 (POM) 和 DEX 治疗:来自 3 期 OCEAN 研究的分析

Pesce, Elisa; Cordiglieri, Chiara; Bombaci, Mauro; Eppenberger-Castori, Serenella; Oliveto, Stefania; Manara, Cristina; Crosti, Mariacristina; Ercan, Caner; Coto, Mairene; Gobbini, Andrea; Campagnoli, Susanna; Donnarumma, Tiziano; Martinelli, Manuele; Bevilacqua, Valeria; De Camilli, Elisa; Gruarin, Paola; Sarnicola, Maria L; Cassinotti, Elisa; Baldari, Ludovica; Viale, Giuseppe; Biffo, Stefano; Abrignani, Sergio; Terracciano, Luigi M; Grifantini, Renata; Schjesvold, F; Ludwig, H; Delimpasi, S; Robak, P; Mateos, M; Sandberg, A; Thuresson, M; Norin, S; Richardson, P; Sonneveld, P

Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study

在来那度胺时代之后,多种药物同时引入治疗复发难治性多发性骨髓瘤是否能带来更好的疗效?来自多发性骨髓瘤真实世界创新(REAL IMM)研究的发现

Petrakis, Ioannis; Kontogiorgis, Christos; Nena, Evangelia; Delimpasi, Sosana; Loutsidi, Natasa E; Spanoudakis, Emmanouil; Intzes, Stergios; Misidou, Christina; Symeonidou, Marianthi; Giannakoulas, Nikolaos; Constantinidis, Theodoros C; Terpos, Evangelos